Exploring the pathogenesis and treatment of IgA nephropathy based on epigenetics

Epigenomics. 2023 Oct;15(19):1017-1026. doi: 10.2217/epi-2023-0318. Epub 2023 Nov 1.

Abstract

IgA nephropathy is the most common primary glomerulonephritis worldwide. However, its exact cause remains unclear, with known genetic factors explaining only 11% of the variation. Recently, researchers have turned their attention to epigenetic abnormalities in immune-related diseases, recognizing their significance in IgA nephropathy's development and progression. This emerging field has revolutionized our understanding of epigenetics in IgA nephropathy research. Though in its early stages, studying IgA nephropathy's epigenetics holds promise for unraveling its pathogenesis and identifying new biomarkers and therapies. This review aims to comprehensively analyze epigenetics' role in IgA nephropathy's development and suggest avenues for potential therapeutic interventions. In the future, assessing and modulating epigenetics may become integral in diagnosing, tailoring treatments and assessing prognoses for IgA nephropathy.

Keywords: IgA nephropathy; epigenetic; histone modifications; methylation; miRNAs; pathogenesis; treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Epigenesis, Genetic*
  • Epigenomics
  • Glomerulonephritis, IGA* / genetics
  • Glomerulonephritis, IGA* / therapy
  • Humans